drugset / Trial / NCT03937479
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to investigate the dose response of RPL554 in patients with moderate to severe CHRONIC OBSTRUCTIVE PULMONARY DISEASE that are still symptomatic despite treatment with a stable background of tiotropium over 4 weeks of treatment. This study is intended to support optimal dose selection for a Phase III program evaluating RPL554 as an add-on treatment to standard of care therapy.
Timeline
- Start
- 2019-05-01
- Primary completion
- 2019-11-15
- Completion
- 2019-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ensifentrine | Unknown | 0.375 mg | Inhaled |
| Subject | Ensifentrine | Unknown | 0.75 mg | Inhaled |
| Subject | Ensifentrine | Unknown | 1.5 mg | Inhaled |
| Subject | Ensifentrine | Unknown | 3 mg | Inhaled |
| Background | Tiotropium | Other / unclassified | — | — |